Inducing tissue specific tolerance in autoimmune disease with tolerogenic dendritic cells

Clinical and Experimental Rheumatology

Volumn 33, Issue , 2015, Pages 97-103

  Suwandi, Jessica S ^a   Toes, René E M ^a   Nikolic, Tatjana ^a   Roep, Bart O ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Loss of self tolerance; Post translational modification; Regulatory T cells; Rheumatoid arthritis; Tolerogenic dendritic cells; Type 1 diabetes; Vitamin D

Indexed keywords

AUTOANTIGEN;

ANIMAL; AUTOIMMUNITY; DENDRITIC CELL; DIABETES MELLITUS, TYPE 1; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; PROCEDURES; REGULATORY T LYMPHOCYTE; TRANSPLANTATION; TREATMENT OUTCOME;

ANIMALS; AUTOANTIGENS; AUTOIMMUNITY; DENDRITIC CELLS; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNOTHERAPY; SELF TOLERANCE; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME;

EID: 84953343238     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. SALLIOT C, GOSSEC L, RUYSSEN-WITRAND A et al.: Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology (Oxford, England) 2007; 46: 327-34.
2. CONWAY R, LOW C, COUGHLAN RJ, O'DONNELL MJ, CAREY JJ: Methotrexate and lung disease in rheumatoid arthritis: a metaanalysis of randomized controlled trials. Arthritis Rheum (Hoboken) 2014; 66: 803-12.
3. THOMAS R: Dendritic cells as targets or therapeutics in rheumatic autoimmune disease. Current Opin Rheumatol 2014; 26: 211-8.
4. THOMPSON AG, THOMAS R: Induction of immune tolerance by dendritic cells: implications for preventative and therapeutic immunotherapy of autoimmune disease. Immunol Cell Biol 2002; 80: 509-19.
5. ANDERSON MS, VENANZI ES, KLEIN L et al.: Projection of an immunological self shadow within the thymus by the aire protein. Science 2002; 298: 1395-401.
6. KYEWSKI B, KLEIN L: A central role for central tolerance. Ann Rev Immunol 2006; 24: 571-606.
7. UNGER WW, VELTHUIS J, ABREU JR et al.: Discovery of low-affinity preproinsulin epitopes and detection of autoreactive CD8 Tcells using combinatorial MHC multimers. J Autoimmun 2011; 37: 151-9.
8. ABREU JR, MARTINA S, VERRIJN STUART AA et al.: CD8 T cell autoreactivity to preproinsulin epitopes with very low human leucocyte antigen class I binding affinity. Clin Exp Immunol 2012; 170: 57-65.
9. de JONG VM, ABREU JR, VERRIJN STUART AA et al.: Alternative splicing and differential expression of the islet autoantigen IGRP between pancreas and thymus contributes to immunogenicity of pancreatic islets but not diabetogenicity in humans. Diabetologia 2013; 56:2 651-8.
10. DOGRA RS, VAIDYANATHAN P, PRABAKAR KR, MARSHALL KE, HUTTON JC, PUGLIESE A: Alternative splicing of G6PC2, the gene coding for the islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP), results in differential expression in human thymus and spleen compared with pancreas. Diabetologia 2006; 49: 953-7.
11. BULEK AM, COLE DK, SKOWERA A et al.: Structural basis for the killing of human beta cells by CD8(+) T cells in type 1 diabetes. Nat Immunol 2012; 13: 283-9.
12. THOMAS R: Dendritic cells and the promise of antigen-specific therapy in rheumatoid arthritis. Arthritis Res Ther 2013; 15: 204.
13. MAKRYGIANNAKIS D, AF KLINT E, LUNDBERG IE et al.: Citrullination is an inflammation-dependent process. Ann Rheum Dis 2006; 65: 1219-22.
14. McINNES IB, SCHETT G: The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365: 2205-19.
15. LING S, CLINE EN, HAUG TS, FOX DA, HOLOSHITZ J: Citrullinated calreticulin potentiates rheumatoid arthritis shared epitope signaling. Arthritis Rheum 2013; 65: 618-26.
16. VERPOORT KN, CHEUNG K, IOAN-FACSINAY A et al.: Fine specificity of the anti-citrullinated protein antibody response is influenced by the shared epitope alleles. Arthritis Rheum 2007; 56: 3949-52.
17. van der WOUDE D, LIE BA, LUNDSTROM E et al.: Protection against anti-citrullinated protein antibody-positive rheumatoid arthritis is predominantly associated with HLADRB1* 1301: a meta-analysis of HLA-DRB1 associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in four European populations. Arthritis Rheum 2010; 62: 1236-45.
18. SHI J, KNEVEL R, SUWANNALAI P et al.: Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci USA 2011; 108: 17372-7.
19. van LUMMEL M, DUINKERKEN G, van VEELEN PA et al.: Posttranslational modification of HLA-DQ binding islet autoantigens in type 1 diabetes. Diabetes 2014; 63: 237-47.
20. FEITSMA AL, van der VOORT EI, FRANKEN KL et al.: Identification of citrullinated vimentin peptides as T cell epitopes in HLADR4-positive patients with rheumatoid arthritis. Arthritis Rheum 2010; 62: 117-25.
21. SAKAGUCHI S: Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Ann Rev Immunol 2004; 22: 531-62.
22. BUCKNER JH: Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol2010; 10: 849-59.
23. LINDLEY S, DAYAN CM, BISHOP A, ROEP BO, PEAKMAN M, TREE TI: Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 2005; 54: 92-9.
24. TREE TI, LAWSON J, EDWARDS H et al.: Naturally arising human CD4 T-cells that recognize islet autoantigens and secrete interleukin-10 regulate proinflammatory T-cell responses via linked suppression. Diabetes 2010; 59: 1451-60.
25. VIGLIETTA V, BAECHER-ALLAN C, WEINER HL, HAFLER DA: Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004; 199: 971-9.
26. SCHNEIDER A, RIECK M, SANDA S, PIHOKER C, GREENBAUM C, BUCKNER JH: The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. J Immunol 2008; 181: 7350-5.
27. EHRENSTEIN MR, EVANS JG, SINGH A et al.: Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004; 200: 277-85.
28. van AMELSFORT JM, JACOBS KM, BIJLSMA JW, LAFEBER FP, TAAMS LS: CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid. Arthritis Rheum 2004; 50: 2775-85.
29. BENSON RA, PATAKAS A, CONIGLIARO P et al.: Identifying the cells breaching self-tolerance in autoimmunity. J Immunol 2010; 184: 6378-85.
30. NIKOLIC T, ROEP BO: Regulatory multitasking of tolerogenic dendritic cells-lessons taken from vitamin d3-treated tolerogenic dendritic cells. Front Immunol 2013; 4: 113.
31. OHNMACHT C, PULLNER A, KING SB et al.: Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity. J Exp Med 2009; 206: 549-59.
32. BAX M, HUIZINGA TW, TOES RE: The pathogenic potential of autoreactive antibodies in rheumatoid arthritis. Semin Immunopathol 2014; 36: 313-25.
33. MARTIN S, WOLF-EICHBAUM D, DUINKERKEN G et al.: Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. New Engl J Med 2001; 345: 1036-40.
34. ROEP BO, PEAKMAN M: Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes. Nature reviews. Immunology 2010; 10: 145-52.
35. COPPIETERS KT, DOTTA F, AMIRIAN N et al.: Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med 2012; 209: 51-60.
36. SANJEEVI CB: HLA-DQ6-mediated protection in IDDM. Hum Immunol 2000; 61: 148-53.
37. FEITSMA AL, van der HELM-van MIL AH, HUIZINGA TW, de VRIES RR, TOES RE: Protection against rheumatoid arthritis by HLA: nature and nurture. Ann Rheum Dis 2008; 67 (Suppl. 3): iii61-3.
38. EERLIGH P, van LUMMEL M, ZALDUMBIDE A et al.: Functional consequences of HLADQ8 homozygosity versus heterozygosity for islet autoimmunity in type 1 diabetes. Genes Immun 2011; 12: 415-27.
39. ABREU JR, ROEP BO: Immune monitoring of islet and pancreas transplant recipients. Curr Diab Rep 2013; 13: 704-12.
40. WILLEMZE A, TROUW LA, TOES RE, HUIZINGA TW: The influence of ACPA status and characteristics on the course of RA. Nature reviews. Rheumatology 2012; 8: 144-52.
41. FERREIRA GB, KLEIJWEGT FS, WAELKENS E et al.: Differential protein pathways in 1,25-dihydroxyvitamin d(3) and dexamethasone modulated tolerogenic human dendritic cells. J Proteome Res 2012; 11: 941-71.
42. UNGER WW, LABAN S, KLEIJWEGT FS, van der SLIK AR, ROEP BO: Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1. Eur J Immunol 2009; 39: 3147-59.
43. KLEIJWEGT FS, LABAN S, DUINKERKEN G et al.: Critical role for TNF in the induction of human antigen-specific regulatory T cells by tolerogenic dendritic cells. J Immunol 2010; 185: 1412-8.
44. van HALTEREN AG, TYSMA OM, van ETTEN E, MATHIEU C, ROEP BO: 1alpha,25-dihydroxyvitamin D3 or analogue treated dendritic cells modulate human autoreactive T cells via the selective induction of apoptosis. J Autoimmun 2004; 23: 233-9.
45. KLEIJWEGT FS, JANSEN DT, TEELER J et al.: Tolerogenic dendritic cells impede priming of naive CD8(+) T cells and deplete memory CD8(+) T cells. Eur J Immunol 2013; 43: 85-92.
46. KLEIJWEGT FS, LABAN S, DUINKERKEN G et al.: Transfer of regulatory properties from tolerogenic to proinflammatory dendritic cells via induced autoreactive regulatory T cells. J Immunol 2011; 187: 6357-64.
47. LARAGIONE T, BRENNER M, SHERRY B, GULKO PS: CXCL10 and its receptor CXCR3 regulate synovial fibroblast invasion in rheumatoid arthritis. Arthritis Rheum 2011; 63: 3274-83.
48. van HALTEREN AG, KARDOL MJ, MULDER A, ROEP BO: Homing of human autoreactive T cells into pancreatic tissue of NOD-scid mice. Diabetologia 2005; 48: 75-82.
49. ARIF S, TREE TI, ASTILL TP et al.: Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J Clin Invest 2004; 113: 451-63.
50. THROWER SL, JAMES L, HALL W et al.: Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study. Clin Exp Immunol 2009; 155: 156-65.
51. HILKENS CM, ISAACS JD: Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now? Clin Exp Immunol 2013; 172: 148-57.
52. GIANNOUKAKIS N, PHILLIPS B, FINEGOLD D, HARNAHA J, TRUCCO M: Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care 2011; 34: 2026-32.
53. TACK CJ, KLEIJWEGT FS, Van RIEL PL, ROEP BO: Development of type 1 diabetes in a patient treated with anti-TNF-alpha therapy for active rheumatoid arthritis. Diabetologia 2009; 52: 1442-4.